Cancer News and Research

Latest Cancer News and Research

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma.

2 Jun 2015

Ariana Pharma joins the GastricGlycoExplorer consortium

This collaboration is carried out within the GastricGlycoExplorer consortium, a European Commission funded project. The consortium aims at discovering and developing new diagnostic signatures by characterizing the sugars that are attached to the surface of gastric tissue. "Glycomics" provides a systematic approach for studying sugars that are naturally present on cell surfaces and its application may lead to determine early markers of gastric cancer.

2 Jun 2015

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

Two new studies conducted by Intermountain Healthcare’s Intermountain Precision Genomics reveal that precision medicine can improve survival in advanced cancer patients – and do so without increasing costs.

2 Jun 2015

ESMO-MCBS tool will help oncology clinicians evaluate most effective anti-cancer medicines

ESMO announced the publication of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients.

2 Jun 2015

$Matched therapy and FoundationOne genomic profiling improve outcomes in patients with refractory cancer$

Matched therapy and FoundationOne genomic profiling improve outcomes in patients with refractory cancer

Foundation Medicine, Inc. and collaborators from the University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute at HealthOne today announced compelling new data demonstrating that matching patients to targeted therapies based on the unique molecular profile of the patient’s advanced cancer leads to improved outcomes across a variety of key measures, including overall survival.

2 Jun 2015

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

A large cooperative-group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with this rare but increasingly common cancer of the blood and marrow.

2 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy.

2 Jun 2015

New treatment option for postmenopausal women with non-invasive breast cancer

Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen.

2 Jun 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).

2 Jun 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) who are current smokers.

2 Jun 2015

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Foundation Medicine, Inc. today presented new data including promising clinical outcomes underscoring the importance of integrating comprehensive genomic profiling with FoundationOne® into clinical oncology care for the treatment of biliary tract cancers.

2 Jun 2015

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.

2 Jun 2015

Northeastern University researchers report two approaches to eradicate Lyme disease

Northeastern University researchers have found that the bacterium that causes Lyme disease forms dormant persister cells, which are known to evade antibiotics. This significant finding, they said, could help explain why it's so difficult to treat the infection in some patients.

2 Jun 2015

Genetically-programmed probiotics could help detect liver cancer metastases early-on

Scientists at the University of California, San Diego and the Massachusetts Institute of Technology have described a new method for detecting liver cancer metastases in mice. The approach uses over-the-counter probiotics genetically programmed to produce signals easily detectable in urine when liver cancer metastases are present.

2 Jun 2015

NSCLC treatment market forecast to reach $7.9 billion by 2020

The Non-Small Cell Lung Cancer treatment market will be driven primarily by the introduction of numerous premium therapies, particularly in second-line and squamous cell treatment settings, which either replace or combine with generic chemotherapies.

2 Jun 2015

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

Fennec Pharmaceuticals, Inc., announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)."

2 Jun 2015

Substantial pharmacogenetic information available on cardiovascular drugs

There is a wealth of published information describing interactions between drugs used to treat cardiovascular disease and the genetic variations that can affect how patients respond to them. But few heart specialists make routine use of this potentially life-saving data.

2 Jun 2015

Veritas Genetics introduces genetic screen for hereditary breast and ovarian cancer risk

Boston-based Veritas Genetics is launching its mission to disrupt the genetic testing industry and bring personalized medicine and prevention to the forefront, allowing individuals to take more control of their health.

2 Jun 2015

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Research led by Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey and colleagues, shows advanced-stage melanoma patients have significant improvement in durable response rate and a trend toward improved survival when treated with a genetically-modified form of a herpes virus, whose native form causes the common cold sore.

2 Jun 2015

Cancer News and Research

Latest Cancer News and Research

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

Ariana Pharma joins the GastricGlycoExplorer consortium

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

ESMO-MCBS tool will help oncology clinicians evaluate most effective anti-cancer medicines

Matched therapy and FoundationOne genomic profiling improve outcomes in patients with refractory cancer

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

New treatment option for postmenopausal women with non-invasive breast cancer

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Helsinn's Akynzeo for CINV prevention receives EC approval

Northeastern University researchers report two approaches to eradicate Lyme disease

Genetically-programmed probiotics could help detect liver cancer metastases early-on

NSCLC treatment market forecast to reach $7.9 billion by 2020

Fennec presents positive interim results from phase III trial of sodium thiosulphate at ASCO 2015

Substantial pharmacogenetic information available on cardiovascular drugs

Veritas Genetics introduces genetic screen for hereditary breast and ovarian cancer risk

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in